UHRF1 depletion suppresses growth of gallbladder cancer cells through induction of apoptosis and cell cycle arrest

Oncology Reports

Volumn 31, Issue 6, 2014, Pages 2635-2643

  Qin, Yiyu ^a   Wang, Jiandong ^a   Gong, Wei ^a   Zhang, Mingdi ^a   Tang, Zhaohui ^a   Zhang, Jun ^a   Quan, Zhiwei ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Cell cycle; Gallbladder cancer; PML; UHRF1

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; PROTEIN UHRF1; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CCAAT ENHANCER BINDING PROTEIN; UHRF1 PROTEIN, HUMAN;

ADULT; AGED; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GALLBLADDER CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; GALLBLADDER TUMOR; GENETICS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 8; CCAAT-ENHANCER-BINDING PROTEINS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; GALLBLADDER NEOPLASMS; HUMANS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84902193241     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3145     Document Type: Article

References (26)

1. Nagorney DM and McPherson GA: Carcinoma of the gallbladder and extrahepatic bile ducts. Semin Oncol 15: 106-115, 1988.
2. Zhu AX, Hong TS, Hezel AF and Kooby DA: Current management of gallbladder carcinoma. Oncologist 15: 168-181, 2010.
3. Takahashi T, Shivapurkar N, Riquelme E, et al: Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis. Clin Cancer Res 10: 6126-6133, 2004. (Pubitemid 39287518)
4. Unoki M, Nishidate T and Nakamura Y: ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 23: 7601-7610, 2004. (Pubitemid 39424918)
5. Jeanblanc M, Mousli M, Hopfner R, et al: The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle. Oncogene 24: 7337-7345, 2005. (Pubitemid 41622238)
6. Geng Y, Gao Y, Ju H and Yan F: Diagnostic and prognostic value of plasma and tissue ubiquitin-like, containing PHD and RING finger domains 1 in breast cancer patients. Cancer Sci 104: 194-199, 2013.
7. Wang F, Zhang P, Ma Y, et al: NIRF is frequently upregulated in colorectal cancer and its oncogenicity can be suppressed by let-7a microRNA. Cancer Lett 314: 223-231, 2012.
8. Unoki M, Kelly JD, Neal DE, Ponder BA, Nakamura Y and Hamamoto R: UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer 101: 98-105, 2009.
9. Unoki M, Daigo Y, Koinuma J, Tsuchiya E, Hamamoto R and Nakamura Y: UHRF1 is a novel diagnostic marker of lung cancer. Br J Cancer 103: 217-222, 2010.
10. Babbio F, Pistore C, Curti L, et al: The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression. Oncogene 31: 4878-4887, 2012.
11. Yang C, Wang Y, Zhang F, et al: Inhibiting UHRF1 expression enhances radiosensitivity in human esophageal squamous cell carcinoma. Mol Biol Rep 40: 5225-5235, 2013.
12. Pi JT, Lin Y, Quan Q, Chen LL, Jiang LZ, Chi W and Chen HY: Overexpression of UHRF1 is significantly associated with poor prognosis in laryngeal squamous cell carcinoma. Med Oncol 30: 613, 2013.
13. 2/M arrest, activation of DNA damage response and apoptosis. Biochem J 435: 175-185, 2011.
14. Cip1/WAF1-dependent DNA damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes Cells 9: 131-142, 2004.
15. Lazcano-Ponce EC, Miquel JF, Muñoz N, et al: Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 51: 349-364, 2001. (Pubitemid 34232782)
16. Jenkins Y, Markovtsov V, Lang W, et al: Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell 16: 5621-5629, 2005. (Pubitemid 41752212)
17. Porter AG and Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6: 99-104, 1999. (Pubitemid 29082297)
18. Vermeulen K, Van Bockstaele DR and Berneman ZN: Apoptosis: mechanisms and relevance in cancer. Ann Hematol 84: 627-639, 2005. (Pubitemid 41554237)
19. Guan D, Factor D, Liu Y, Wang Z and Kao HY: The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein. Oncogene 32: 3819-3828, 2013.
20. Chang HJ, Yoo BC, Kim SW, Lee BL and Kim WH: Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol Oncol Res 13: 326-335, 2007. (Pubitemid 351287314)
21. Krieghoff-Henning E and Hofmann TG: Role of nuclear bodies in apoptosis signalling. Biochim Biophys Acta 1783: 2185-2194, 2008.
22. Reineke EL, Liu Y and Kao HY: Promyelocytic leukemia protein controls cell migration in response to hydrogen peroxide and insulin-like growth factor-1. J Biol Chem 285: 9485-9492, 2010.
23. Kim WH, Kang KH, Kim MY and Choi KH: Induction of p53-independent p21 during ceramide-induced G1 arrest in human hepatocarcinoma cells. Biochem Cell Biol 78: 127-135, 2000. (Pubitemid 30353770)
24. Zuo S, Liu C, Wang J, et al: IGFBP-rP1 induces p21 expression through a p53-independent pathway, leading to cellular senescence of MCF-7 breast cancer cells. J Cancer Res Clin Oncol 138: 1045-1055, 2012.
25. Shen Y: Advances in the development of siRNA-based therapeutics for cancer. IDrugs 11: 572-578, 2008.
26. Unoki M, Kumamoto K and Harris CC: ING proteins as potential anticancer drug targets. Curr Drug Targets 10: 442-454, 2009.